NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that revenues for its fourth quarter increased 16 percent year over year on the strength of its assays and related products as well as consumables sales.

Total revenues for the three months ended Dec. 31, 2012 were $55.5 million, up from $47.9 million in the year-ago period, and beat the consensus Wall Street estimate of $54.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.